{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:32:33Z","timestamp":1788582753745,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-014"],"award-info":[{"award-number":["2021-I2M-1-014"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.intimp.2024.111799","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T07:08:41Z","timestamp":1709881721000},"page":"111799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["New advances in the study of PD-1\/PD-L1 inhibitors-induced liver injury"],"prefix":"10.1016","volume":"131","author":[{"given":"Meijun","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-5127","authenticated-orcid":false,"given":"Chunyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.111799_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11684-022-0927-0","article-title":"Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy","volume":"16","author":"Li","year":"2022","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.111799_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of Pd-1\/Pd-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2024.111799_b0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111799_b0020","first-page":"727","article-title":"Pd-1\/Pd-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"7528","key":"10.1016\/j.intimp.2024.111799_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-Pd-L1 antibody Mpdl3280a in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.111799_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114824","article-title":"Mechanisms of Cd8(+) T cell exclusion and dysfunction in cancer resistance to anti-Pd-(L)1","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"10304","key":"10.1016\/j.intimp.2024.111799_b0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2024.111799_b0040","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"Pd-1\/Pd-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2021.103324","article-title":"Pd-1\/Pd-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis","volume":"43","author":"Chen","year":"2022","journal-title":"Am. J. Otolaryngol."},{"issue":"10","key":"10.1016\/j.intimp.2024.111799_b0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00228-020-02903-2","article-title":"Hepatotoxicity in patients with solid tumors treated with Pd-1\/Pd-L1 inhibitors alone, Pd-1\/Pd-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111799_b0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111799_b0060","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111799_b0065","first-page":"26","article-title":"Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience","author":"da Silva","year":"2021","journal-title":"Ann. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0070","doi-asserted-by":"crossref","first-page":"101491","DOI":"10.1016\/j.clinre.2020.06.016","article-title":"Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal","volume":"45","author":"Gauci","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.111799_b0075","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","article-title":"Anti-Pd-1, Pd-L1 blockade immunotherapy employed in treating hepatitis b virus infection-related advanced hepatocellular carcinoma: a literature review","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"issue":"10236","key":"10.1016\/j.intimp.2024.111799_b0080","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage iv melanoma with no evidence of disease (immuned): a Randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"issue":"9948","key":"10.1016\/j.intimp.2024.111799_b0085","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet."},{"issue":"19","key":"10.1016\/j.intimp.2024.111799_b0090","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"adjuvant pembrolizumab versus placebo in resected stage iii melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.111799_b0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"Pd-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0100","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2 single-arm trial.","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111799_b0105","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.111799_b0110","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage iv metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2024.111799_b0115","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111799_b0120","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous nsclc (impower131): results from a randomized phase iii trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"10257","key":"10.1016\/j.intimp.2024.111799_b0125","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (impassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous Pd(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111799_b0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing Pd-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12072-011-9279-6","article-title":"Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management","volume":"7","author":"Liu","year":"2013","journal-title":"Hepatol. Int."},{"issue":"32","key":"10.1016\/j.intimp.2024.111799_b0145","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J. Gastroenterol"},{"issue":"10","key":"10.1016\/j.intimp.2024.111799_b0150","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep."},{"issue":"10","key":"10.1016\/j.intimp.2024.111799_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108901","article-title":"Gene expression changes in cytokine and chemokine receptors in association with melanoma liver metastasis","volume":"24","author":"Koroknai","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.111799_b0160","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111799_b0165","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of Pd-1 inhibition in metastatic cancer patients with a history of liver transplantation: the mayo clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.111799_b0170","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients","volume":"6","author":"Munker","year":"2018","journal-title":"United European Gastroenterol. J."},{"issue":"1","key":"10.1016\/j.intimp.2024.111799_b0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for Ctla-4 and Pd-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2024.111799_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.964779","article-title":"Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: a systematic review and meta analysis","volume":"12","author":"Zhong","year":"2022","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111799_b0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111799_b0190","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterol."},{"key":"10.1016\/j.intimp.2024.111799_b0195","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15739","article-title":"Mechanisms and aetiology-dependent treatment of acute liver failure","author":"Lemmer","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.intimp.2024.111799_b0200","article-title":"Clinical characteristics of Ici-Related pancreatitis and cholangitis including radiographic and endoscopic findings","volume":"10","author":"Nakano","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.intimp.2024.111799_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-Related adverse events of checkpoint inhibitors: insights into immunological dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.111799_b0210","article-title":"Pd-1\/Pd-L1 inhibitors in patients with preexisting autoimmune diseases","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.intimp.2024.111799_b0215","doi-asserted-by":"crossref","first-page":"1077468","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-Mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111799_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081913","article-title":"The role of myeloid cells in hepatotoxicity related to cancer immunotherapy","volume":"14","author":"Gudd","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2024.111799_b0225","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-Mediated acquiredresistance to immune checkpoint inhibitors.","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.intimp.2024.111799_b0230","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2024.111799_b0235","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111799_b0240","unstructured":"Eviq. Management of Immune-Related Adverse Events, 2022. <Https:\/\/Www.Eviq.Org.Au\/Clinical-Resources\/Side-Effect-and-Toxicity-Management\/Immunological\/1993-Management-of-Immune-Related-Adverse-Events#Hepatotoxicity> (Accessed 1 November 2023)."},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020101","article-title":"Checkpoint inhibitors and hepatotoxicity","volume":"9","author":"Malnick","year":"2021","journal-title":"Biomedic."},{"issue":"10","key":"10.1016\/j.intimp.2024.111799_b0250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.111799_b0255","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111799_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246168","article-title":"A novel mouse for checkpoint inhibitor-induced adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2024.111799_b0265","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2217\/imt-2016-0057","article-title":"Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma","volume":"8","author":"Simonelli","year":"2016","journal-title":"Immunother."},{"key":"10.1016\/j.intimp.2024.111799_b0270","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6391712","article-title":"Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients","author":"Imoto","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111799_b0275","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2169\/internalmedicine.9851-17","article-title":"Nivolumab induces sustained liver injury in a patient with malignant melanoma","volume":"57","author":"Matsubara","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.intimp.2024.111799_b0280","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-Pd-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2024.111799_b0285","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.pathol.2017.07.010","article-title":"Histopathology of pembrolizumab-induced hepatitis: a case report","volume":"49","author":"Aivazian","year":"2017","journal-title":"Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111799_b0290","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111799_b0295","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.111799_b0300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1208\/s12248-021-00629-2","article-title":"Deciphering the dynamic complexities of the liver microenvironment - toward a better understanding of immune-mediated liver injury caused by immune checkpoint inhibitors (Ilici)","volume":"23","author":"Wang","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.intimp.2024.111799_b0305","doi-asserted-by":"crossref","unstructured":"European association for the study of the liver. electronic address eee, clinical practice guideline panel c, panel m, representative EGB. easl clinical practice guidelines: Drug-induced liver injury, J. Hepatol. 70(6) (2019) 1222\u20131261 10.1016\/j.jhep.2019.02.014 Epub 20190327.","DOI":"10.1016\/j.jhep.2019.02.014"},{"issue":"1","key":"10.1016\/j.intimp.2024.111799_b0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (Sitc) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"suppl_4","key":"10.1016\/j.intimp.2024.111799_b0315","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111799_b0320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"10.1016\/j.intimp.2024.111799_b0325","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int."},{"issue":"17","key":"10.1016\/j.intimp.2024.111799_b0330","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111799_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101619","article-title":"The current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity.","volume":"28","author":"Xing","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2024.111799_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113313","article-title":"Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology","volume":"193","author":"Alouani","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2024.111799_b0345","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12328-023-01832-8","article-title":"Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil","volume":"16","author":"Sato","year":"2023","journal-title":"Clin. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111799_b0350","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/hep.31396","article-title":"Severe refractory checkpoint inhibitor-related hepatitis reversed with anti-thymocyte globulin and n-acetylcysteine","volume":"72","author":"Motomura","year":"2020","journal-title":"Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.111799_b0355","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-Pd-1-induced high-grade hepatitis associated with corticosteroid-resistant t cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.intimp.2024.111799_b0360","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/annonc\/mdw041","article-title":"Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies","volume":"27","author":"Sanmamed","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924003175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924003175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T01:42:58Z","timestamp":1731721378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924003175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":72,"alternative-id":["S1567576924003175"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111799","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New advances in the study of PD-1\/PD-L1 inhibitors-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111799"}}